Curated News
By: NewsRamp Editorial Staff
May 28, 2026
LakeShore Biopharma Calls EGM to Vote on Going Private Merger
TLDR
- LakeShore Biopharma shareholders vote June 19 on merger that will take the company private, delisting its shares.
- The merger agreement, approved by a special committee, will merge Merger Sub into LakeShore Biopharma, making it a private subsidiary.
- Going private may enable LakeShore to focus on developing vaccines for rabies, hepatitis B, and influenza, benefiting global health.
- LakeShore Biopharma, formerly YS Biopharma, uses a proprietary PIKA platform to boost immune responses against viruses and cancer.
Impact - Why it Matters
This merger matters because it will take LakeShore Biopharma private, removing its shares from public trading and altering shareholder liquidity. The decision reflects a trend of biotech companies seeking private ownership to focus on R&D without quarterly earnings pressure. For investors, it means potential exit at the merger price, but loss of public market access. The move could accelerate the company's vaccine development, particularly its PIKA® platform, impacting global health by potentially speeding up treatments for Rabies, Hepatitis B, and cancer.
Summary
LakeShore Biopharma Co., Ltd (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company focused on vaccines and therapeutic biologics, has announced an extraordinary general meeting (EGM) of shareholders scheduled for June 19, 2026, in Beijing. The EGM will consider a proposal to approve the previously announced merger agreement with Oceanpine Skyline Inc. and its subsidiary, Oceanpine Merger Sub Inc. The merger, if approved, will result in LakeShore Biopharma becoming a privately held company, delisting from the OTC Pink tier and deregistering its shares and warrants under the Securities Exchange Act of 1934. The company's board, following the unanimous recommendation of a special committee of independent directors, has authorized the merger and urges shareholders to vote in favor.
The merger agreement, dated November 4, 2025, and amended on April 29, 2026, outlines that at the effective time, Merger Sub will merge into LakeShore Biopharma, with the company surviving as a wholly owned subsidiary of Parent. This move will transition LakeShore Biopharma from a publicly traded entity to a private company, impacting its stock listing and regulatory reporting obligations. Shareholders of record as of May 27, 2026, are entitled to vote at the EGM. Additional details are available in the transaction statement on Schedule 13E-3 and the proxy statement filed with the U.S. Securities and Exchange Commission (SEC), accessible via the SEC's website or by contacting the company's investor relations.
LakeShore Biopharma, previously known as YS Biopharma, leverages its proprietary PIKA® immunomodulating technology platform to develop vaccines and therapeutics for infectious diseases like Rabies, Hepatitis B, and Influenza, as well as cancer. Operating in China, Singapore, and the Philippines, the company is led by a management team with deep local and global biopharmaceutical expertise. The merger represents a significant strategic shift, allowing the company to operate privately and focus on long-term goals without the pressures of public market scrutiny. For more information, visit the company's website at https://investors.lakeshorebio.com/. View the original release on NEWMEDIAWIRE.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, LakeShore Biopharma Calls EGM to Vote on Going Private Merger
